PURPOSE: Neoadjuvant chemotherapy (NAC) can downstage invasive bladder cancers prior to radical cystectomy (RC) and improve overall survival. However, the optimal management in patients with persistent non-organ confined disease (pT3-T4 and/or pN+) following RC has not been completely defined. The aim of this study was to describe outcomes associated with the use of adjuvant chemotherapy (AC) in patients with residual non-organ confined cancer at RC following NAC. MATERIALS AND METHODS: Using data from a high-volume referral institution, pT3-T4 and/or pN+ patients who received NAC and then also RC were identified. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were assessed with Kaplan-Meier analysis. RESULTS: From 2001 to 2013, 161 patients received NAC and then RC. Eighty-eight pT3-T4 and/or pN+ patients were identified. Twenty-nine (33 %) received AC. Adjuvant chemotherapy in the majority of patients was carboplatin-based (16), followed by cisplatin (8) and other, mainly taxane-containing regimens (5). The median RFS was 17.5 months in the AC and 13.7 months in the non-AC group (p = 0.78). AC remained an insignificant predictor for RFS after adjusting for pT, pN and margin status (HR 0.89, 95 % CI 0.48-1.68]). CSS was 23 and 22 months (p = 0.65) and remained insignificant after adjusting for pathologic confounders. CONCLUSIONS: In our current study population, adjuvant conventional cytotoxic chemotherapy was not associated with significant improvements in RFS or CSS. The choice of AC regimens, and incorporation of newer treatments, may be the key for improving outcomes in this high-risk patient group.
PURPOSE: Neoadjuvant chemotherapy (NAC) can downstage invasive bladder cancers prior to radical cystectomy (RC) and improve overall survival. However, the optimal management in patients with persistent non-organ confined disease (pT3-T4 and/or pN+) following RC has not been completely defined. The aim of this study was to describe outcomes associated with the use of adjuvant chemotherapy (AC) in patients with residual non-organ confined cancer at RC following NAC. MATERIALS AND METHODS: Using data from a high-volume referral institution, pT3-T4 and/or pN+ patients who received NAC and then also RC were identified. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were assessed with Kaplan-Meier analysis. RESULTS: From 2001 to 2013, 161 patients received NAC and then RC. Eighty-eight pT3-T4 and/or pN+ patients were identified. Twenty-nine (33 %) received AC. Adjuvant chemotherapy in the majority of patients was carboplatin-based (16), followed by cisplatin (8) and other, mainly taxane-containing regimens (5). The median RFS was 17.5 months in the AC and 13.7 months in the non-AC group (p = 0.78). AC remained an insignificant predictor for RFS after adjusting for pT, pN and margin status (HR 0.89, 95 % CI 0.48-1.68]). CSS was 23 and 22 months (p = 0.65) and remained insignificant after adjusting for pathologic confounders. CONCLUSIONS: In our current study population, adjuvant conventional cytotoxic chemotherapy was not associated with significant improvements in RFS or CSS. The choice of AC regimens, and incorporation of newer treatments, may be the key for improving outcomes in this high-risk patient group.
Authors: Jeffrey J Leow; William Martin-Doyle; Padma S Rajagopal; Chirayu G Patel; Erin M Anderson; Andrew T Rothman; Richard J Cote; Yuksel Urun; Steven L Chang; Toni K Choueiri; Joaquim Bellmunt Journal: Eur Urol Date: 2013-08-28 Impact factor: 20.096
Authors: Adrian S Fairey; Siamak Daneshmand; David Quinn; Tanya Dorff; Ryan Dorin; Gary Lieskovsky; Anne Schuckman; Jie Cai; Gus Miranda; Eila C Skinner Journal: Urol Oncol Date: 2012-11-07 Impact factor: 3.498
Authors: Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes Journal: Eur Urol Date: 2011-03-23 Impact factor: 20.096
Authors: R Millikan; C Dinney; D Swanson; P Sweeney; J Y Ro; T L Smith; D Williams; C Logothetis Journal: J Clin Oncol Date: 2001-10-15 Impact factor: 44.544
Authors: Matthew I Milowsky; David M Nanus; Fernando C Maluf; Svetlana Mironov; Weiji Shi; Alexia Iasonos; Jamie Riches; Ashley Regazzi; Dean F Bajorin Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Guru Sonpavde; Gregory R Pond; Toni K Choueiri; Stephanie Mullane; Guenter Niegisch; Peter Albers; Andrea Necchi; Giuseppe Di Lorenzo; Carlo Buonerba; Antonio Rozzi; Kazumasa Matsumoto; Jae-Lyun Lee; Hiroshi Kitamura; Haruki Kume; Joaquim Bellmunt Journal: Eur Urol Date: 2015-08-08 Impact factor: 20.096
Authors: Thomas Seisen; Asha Jamzadeh; Jeffrey J Leow; Morgan Rouprêt; Alexander P Cole; Stuart R Lipsitz; Adam S Kibel; Paul L Nguyen; Maxine Sun; Mani Menon; Joaquim Bellmunt; Toni K Choueiri; Quoc-Dien Trinh Journal: JAMA Oncol Date: 2018-02-01 Impact factor: 31.777
Authors: Wojciech Krajewski; Łukasz Nowak; Marco Moschini; Sławomir Poletajew; Joanna Chorbińska; Andrea Necchi; Francesco Montorsi; Alberto Briganti; Rafael Sanchez-Salas; Shahrokh F Shariat; Juan Palou; Marek Babjuk; Jeremy Yc Teoh; Francesco Soria; Benjamin Pradere; Paola Irene Ornaghi; Aleksandra Pawlak; Janusz Dembowski; Romuald Zdrojowy Journal: J Clin Med Date: 2021-02-08 Impact factor: 4.241